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A b s t r a c t  
The aim of the present work was to formulate and evaluate betahistine-loaded chitosan 
microspheres intended for nasal delivery with focus on their mucoadhesive properties.  
Betahistine-loaded chitosan microspheres were obtained via W/O emulsion solvent evaporation 
technique and were characterized for particle size, surphace morfology and entrapment efficiency. 
FTIR spectroscopy was carried out to evaluate drug-polymer interaction and powder X-ray 
diffractometry was applied to investigate crystallinity transformations. Tensile studies were carried 
out using sheep nasal mucosa to evaluate in vitro mucoadhesion. Drug release into phosphate 
buffer saline pH 7.4 was performed and dissolution profiles of the formulations were obtained.  
The results showed that the microspheres were spherical in shape having smooth surface and mean 
particle size of 3.82 øm to 7.69 øm which is appropriate for optimum deposition in the nasal cavity. 
The mean particle size increased when chitosan solutions with higher viscosity were used. In vitro 
mucoadhesion studies indicated that chitosan microspheres had good mucoadhesive properties and 
could adequately adhere to nasal mucosa. It was observed that polymer concentration 
enhancement led to increased mucoadhesive strength. Betahistine release studies from the 
microspheres showed similar and slightly icreasing dissolution profiles. 
Acording to the obtained results, betahistine-loaded chitosan microspheres prepared by solvent 
evaporation method proved to be capable of sustained release and could be used via nasal route as 
an alternative to oral administration. 
Keywords: MénièreÊs syndrome, chitosan microparticles, mucoadhesion, nasal delivery, sustained 
release. 
Introduction 
Betahistine dihydrochloride (BET) is a histamine analogue, which is 
currently prescribed for the symptomatic treatment of vestibular 
disorders of central and peripheral origin. BET improves the 
microcirculation of the inner ear resulting in reduced endolymphatic 
pressure in the labyrinth and is, therefore widely used to relieve the 
symptoms associated with  MénièreÊs syndrome [1]. The 
mechanism by which BET alters this microcirculation and its 
interaction with the histaminergic system is now well established. 
BET primarily acts like a partial histamine H1 receptor agonist and 
a more potent histamine H3 receptor antagonist. Stimulating the 
H1 receptors in the inner ear causes a vasodilatory effect and 
increased permeability in the blood vessels which results in 
reduced endolymphatic pressure. By blocking the histamine H3 
autoreceptors, BET increases the synthesis and release of 
histamine in the tuberomammillary nuclei which can further 
increase the direct H1 agonist activity [2,3]. In clinical practice, BET 
is generally administered orally at a dose range 24 to 48 mg/day 
divided into three to four doses daily. Studies with radio-labelled 
BET have demonstrated a plasma half life of 3.4 hours which 
necessitates frequent administration of the drug and may lead to 
noncomplience, especially in elderly patients [1,4]. 
It was thus challenging to be able to design a sustained release 
formulation of BET which allows a reduction of the frequency of 
dose while keeping drug concentration within the therapeutic 
range. Since the drug is freely soluble in water, specific 
technological approaches are required to control drug release. 
Recently there has been a considerable interest in alternative 
routes of administration as a means of drug delivery. Among them, 
nasal delivery seems to be an appropriate way to prevent 
conditions like nausea and vomiting associated with MénièreÊs 
syndrome [5]. The widespread interest arises from the particular 
anatomical, physiological and histological characteristics of the 
nasal cavity, which provides rapid systemic drug absorption and 
quick onset of action. The nasal mucosa is easily accessible, highly 
vascularised and permeable; it provides rapid drug absorption rate 
and plasma drug profiles sometimes almost identical to those from 
intravenous injections. In addition, intranasal administration avoids 
the gastrointestinal and hepatic presystemic metabolism, 
enhancing drug bioavailability compared to gastrointestinal 
absorption [6,7]. The nasal delivery seems to be a favourable way 
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to circumvent the obstacles for blood-brain barrier allowing direct 
drug delivery to the central nervous system via the olfactory 
neurons [8].  
Despite the numerous advantages, there are certain limiting factors 
like mucociliary clearance and enzymatic activity, that adversely 
affect the bioavailability of drugs and must be considered when 
developing a nasal formulation [9]. To overcome the problem with 
the low bioavailability of drugs administered via nasal route, 
different approaches have been studied.   The use of 
mucoadhesive polymers has proven to be effective in providing an 
intimate contact with the mucosa and thereby, prolonging the 
residence time of drug formulations in the nasal cavity, resulting in 
improved nasal drug absorption. Mucoadhesion is generally 
achieved with the use of polymers; various mucoadhesive 
polymers such as gelatin, chitosan, cellulose derivatives, 
hyaluronic acid, starch, polyacrylic acids (eg. carbopol, polymethyl 
methacrylate) in different forms have been studied for the mucosal 
delivery of small molecules and macromolecular drugs [10].   
A growing interest towards the development of polymeric carriers 
as a means of drug delivery has been noticed recently. 
Microspheres constitute an important part of these particulate drug 
delivery systems by virtue of their small size and efficient carrier 
capacity; coupling of mucoadhesive properties of polymers to 
microparticulate systems has additional advantages [11]. 
Mucoadhesive microspheres form a gel-like layer, which is cleared 
slowly from the nasal cavity. The prolonged residence time at the 
application site contributes to improved therapeutic performance of 
drugs namely prolonged drug release and a reduction in frequency 
of drug administration. Thus patient comfort and compliance are 
improved. Another benefit is the protection of the encapsulated 
drug from hazardous conditions and enhance drug stability [12]. 
Chitosan microspheres have received considerable attention as 
nasal drug delivery systems [13]. Chitosan, being biodegradable, 
biocompatible, non-toxic and bioadhesive polymer is a suitable 
excipient for use in biomedical and pharmaceutical formulations 
[14]. Chitosan is a cationic polysaccharide, derived by the 
deacetylation of chitin. Chitosan is positively charged due to its 
amino groups and able to interact strongly with the negatively 
charged mucus layer of the nasal epithelium [15]. This is to provide 
a longer contact time for drug transport across the nasal 
membrane, before the formulation is cleared by the mucociliary 
clearance mechanism. In addition, chitosan has been shown to 
increase the paracellular transport of polar drugs by transiently 
opening the tight junctions between the epithelial cells [16]. 
In the present study chitosan microspheres intended for nasal 
delivery of BET were prepared by emulsification solvent-
evaporation technique. The influence of different formulation 
variables, namely, chitosan concentration and drug-polymer ratio 
on the production yield, particle size, drug entrapment efficiency 
and in vitro mucoadhesion was investigated. Additionally, in vitro 
drug release from the chitosan microspheres was studied. 
Materials and Methods 
Betahistine dihydrochloride, chitosan (from shrimp shells, low 
viscousity, degree of deacetylation >75%),  sorbitan monooleate 80 
(Span 80) and petroleum ether were purchased from Sigma-Aldrich 
Chemie GmbH (Taufkirchen, Germany). All other reagents and 
solvents were of analytical grade and were used as provided. 
Preparation of chitosan microspheres 
Chitosan microspheres were prepared by single emulsion/solvent 
evaporation technique using liquid paraffine as external phase. 
Briefly, chitosan was dissolved in deionized water containing 2% v/ 
v acetic acid. Accurately weighed amount of BET was added to the 
polymer solution  by continuously stirring until a homogeneous 
solution was obtained. To form a single W/O emulsion, drug-
polymer solutions were slowly added dropwise to 100 ml preheated 
liquid paraffine containing 0.5% w/v  Span 80 as an emulsifying 
agent at a constant stirring rate of 1100 rpm for 3.5 hours using a 
two blade stirrer ES (Velp Scientifica, Usmate, Italy). The 
temperature was maintained at 65ÀC througout the process which 
helps in evaporation of the aqueous acidic phase and solidification 
of the microspheres. The hardened microspheres were separated 
by vacuum filtration and washed several times with petroleum ether 
to remove oil. Finally, microspheres were air dried for 24 h and 
then stored in vacuum desiccator for further use. To study the 
influence of different formulation variables on chitosan 
microspheres, four batches of formulations, labeled M1  - M4 
were prepared by varying BET and chitosan concentrations and 
drug/polymer ratio as given in Table 1. 
 
Table 1. Composition and physicochemical properties of BET loaded microspheres. 
Formulation 
code 
Drug 
concentration, 
% 
Polymer 
concentration, 
% 
Drug/polymer 
ratio 
Yield
 (% μ SD)* 
Entrapment 
efficiency 
 (% μ SD)** 
Mean particle 
size (mμ SD)** 
M1 1 1 1:1 68.46 μ 4.98 69.37  μ 0.91 3.82 μ 0.14
M2 1 1.5 1:1.5 73.33 μ 6.67 93.02  μ 0.98 4.49 μ 0.24
M3 1 2 1:2 76.57 μ 6.44 93.85  μ 2.51 4.52 μ 0.33
M4 2 2 1:1 84.23 μ 6.73 98.27  μ 0.73 7.69 μ 0.33
            *n=5; **n=3 
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Microsphere characterization 
Production yield, drug content and incorporation  
efficiency 
The production yields of microspheres of various batches were 
calculated using the weight of finally dried microspheres (W1) with 
respect to the initial total quantity of the drug and polymer used 
(W2). Production yields were calculated as per the formula 
mentioned below, and reported in Table 1. 
 % Production Yield =W1/W2 X 100 
The actual drug content of all the formulations was determined 
spectrophotometrically. BET- loaded microspheres were dispersed 
in 20 ml 2 % v/v aquaeous acetic acid solution by agitation in 
ultrasonicator (Siel UST7.8-200, Gabrovo, Bulgaria) for 30 minutes 
to dissolve the polymer and extract the drug. After filtration, drug 
concentration was determined after proper dilution using an 
Ultrospec 3300 pro UV/Visible Spectrophotometer (Biochrom Ltd., 
Cambridge, UK) at a wavelength of 261 nm. The Drug Entrapment 
Efficiency (DEE) was calculated according to the following 
equation:  
DEE % = (Actual drug content/ Theoretical drug content) ï 100 
The drug entrapment efficiency for the formulations M1 to M4 is 
reported in Table 1. 
Particle size analysis 
All batches of microspheres were studied for shape and size using 
optical microscope (Eclipse 80i, Nikon Engineering Co., Ltd., 
Japan) equipped with a camera (DS-Qi1) and computer controlled 
image analysis software (NIS-Elements, Nikon, Japan). At least 
one hundred microspheres were measured randomly and the 
average particle size was determined using the EdmondsonÊs 
equation: 
Dmean= ∑ nd / ∑ n, 
where where n= number of microspheres observed and d=mean 
size range. 
Morphological examination 
Scanning Electron Microscopy (Philips SEM 515, Eindhoven, The 
Netherlands) was used to examine the shape and surface 
morphology of the microsphere formulations. The samples were 
loaded on a copper sample holder and sputter coated with carbon 
followed by gold using vacuum evaporator (BH30). The images 
were recorded at 25 kV acceleration voltage using various 
magnifications. 
FTIR spectrophotometry 
In order to evaluate the integrity and compatibility of the 
drug/polymer formulations, FTIR spectra were obtained. The 
spectra of betahistine (Fig. 3a), BET-free (placebo) particles (Fig. 
3b) and model systems (Fig. 3c) were recorded on Nicolet Avatar 
330 FTIR spectrometer (64 scans, 4 nm resolution, spectral range 
4000-400 cm-1) as spectra of transmittance and converted as 
absorption spectra with EZ Omnic softwear. The samples were 
prepared by KBr pellet method. 
Thermal analysis 
Differential thermal analysis and thermogravimetric analysis were 
performed on pure drug, chitosan, placebo and drug-loaded 
microspheres and the results are illustrated in Figure 4.  
A Stanton Redcroft TG-DTA simultaneous thermal analyser STA 
1500 was used in the measurements, and a heating rate of 10ÀC 
min-1 in an argon atmosphere over a temperature range of 10ĈC to 
450ĈC was applied. 
Powder X-ray diffraction (XRD) studies 
X-ray diffraction studies were carried out using powder X-ray 
diffractometer (D2 Phaser, Bruker AXS GmbH, Karlsruhe, 
Germany) to get the idea of the crystallinity. The samples were 
irradiated with monochromatised CuKđ radiation and analyzed 
between from 4Ĉ to 60Ĉ (2θ), applying 30 kV, 10 mA.  Powder X-ray 
diffractograms of pure drug, chitosan and formulation (M1-M4) are 
given in Figure 5. 
In vitro mucoadhesive strength determination 
The in vitro mucoadhesion of microspheres was investigated using 
freshly isolated sheep nasal mucosa [17,18]. The mucosa was 
obtained from an authorized local abattoir. Within 60 min of 
slaughtering the animal, the mucosa was excized and fixed still on 
a plastic support. About 90 mg of microspheres were compressed 
into a 13 mm disc-shaped tablet which was attached to a 
coveglass (20 x 20 mm) using cyanoacrylate glue and mounted on 
the sensor of  TRI201 Isometric force transducer (LSI LETICA 
Scientific Instruments, Panlab S.L., Barcelona, Spain). The test 
tablet and the mucosal surface were brought into contact in 
phosphate buffered saline (PBS pH 7.4) at a room temperature. 
The force required for detachment of the tablet from the lower 
surface after certain time of contact was measured as a function of 
displacement, by lifting the glass support at a constant rate of 1 
mm min-1 until total separation of the components was achieved. 
The reported values (Fig. 6) are the average of five different 
tablets.  
In vitro drug release study 
In vitro release of BET from the prepared microparticles was 
studied by diffusion with dialysis bag [19]. The dialysis membrane 
(Sigma, MWCO 12000 Da) was cut into equal pieces (6 x 2.5 cm) 
and soaked in distilled water for 24 h before use. An accurately 
weighed quantity of microparticles (equivalent to 10 mg BET) was 
suspended in 1 mL of PBS (pH7.4) and placed in the dialysis bag 
with the two ends fixed by thread. The bag was attached to the 
paddles of USP type II dissolution tester (AT7 Sotax, Allschwil, 
Switzerland) and put into 500 mL PBS (pH 7.4) dissolution 
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medium. The rotation speed was set at 50 rpm and the 
temperature of the dissolution medium was maintained at 37μ 
0.5ĈC. Samples of 1 mL were withdrawn from receptor 
compartment at regular time intervals and replaced with the same 
amount of fresh PBS. The samples were then analyzed 
spectrophotometrically as described earlier. The in vitro release 
study was performed in triplicate for each sample. Dissolution 
profiles of formulation batches M1 - M4 are given in Figure 7. 
Statistical Analysis 
All experiments were repeated at least three times. Results are 
expressed as means μ standard deviation (SD). Statistical analysis 
was carried out employing one-way ANOVA followed by 
studentized range test using the SPSS Statistics 11.5. A p-value 
less than 0.05 was considered statistically significant. 
Results and Discussion 
Preparation of the microspheres 
The solvent evaporation technique described here appears to be a 
suitable method for the preparation of chitosan microspheres 
loaded with BET due to its simplicity, rapidness and reproducibility 
[20,21]. Four samples of drug-loaded, and corresponding 
betahistine-free microsperes were prepared using different 
concentrations of BET and chitosan (1.0%, 1.5% and 2.0% w/v) 
and varying drug/polymer ratio (1:1, 1:1.5 and 1:2) to investigate 
modifications of the production yield, particle size, surface 
topography, drug entrapment efficiency and release behaviour. The 
production yield of microspheres was improved from 68.46% to 
84.23% when the concentration of the polymer increased (Table 1).  
Drug loading and encapsulation efficiency 
BET loaded microspheres were produced with a high drug 
entrapment efficiency. Higher polymer concentration in the 
emulsion droplets led to an enhancement of the efficiency of BET 
entrapment from 69.37 % to 98.27 % (Table 1). Probably, the 
higher viscosity of chitosan solution tended to restrict diffusion of 
the drug in the surroundings and enhanced the drug entrapment 
efficiency [22]. These results indicate very good reproducibility of 
the solvent evaporation method. 
Optical microscopy 
Optical microscopy of BET-loaded microparticles revealed 
spherical geometry with few aggregates formed in all the 
preparations. The particle size of each microsphere formulation is 
reported in Table 1. Mean sizes of the formulations ranged from 
3.82 to 7.69 μm which is considered to be appropriate for optimum 
deposition in the nasal cavity [23]. Increase in chitosan 
concentration in a fixed volume of aqueous phase resulted in larger 
particle diameter, which may be due to the fact that the higher the 
polymer concentration, the higher crosslinking degree. It could be 
postulated that higher concentration of polymer in the sample led to 
an enhanced frequency of collisions, resulted in fusion of 
semiformed particles, and finally increased the size of the 
microspheres [24]. Photomicrographs of the microspheres are 
presented in Figure 1. 
 
 
 
 
 
 
 
 
 
 
                
          Figure 1. Photomicrographs of BET-loaded microspheres M1(a), M2(b), M3(c) and M4(d) taken at magnification 200x 
(a (b
)
(c (d
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Scanning electron microscopy 
Studies using SEM provided a better understanding of the 
morphological characteristics of the microspheres. SEM images of 
BET-loaded and placebo microspheres are presented at Figures 
2(a), 2(b), 2(c) and 2(d), respectively. The placebo chitosan 
microspheres appeared to have a different morphology when 
compared to the BET-loaded chitosan microspheres. The placebo 
microspheres exhibited smooth surface while drug loaded 
microspheres appeared to have crumpled surface with many 
wrinkles and gaps between them. The results showed that the 
drug/polymer ratio affected the morphological characteristics of the 
microspheres. As the polymer ratio increased, more furrowed 
microspheres with larger gaps were obtained. During the solvent 
elimination process a crust is formed on the outer surface of the 
droplets. When the inner water phase is evaporated the crust is 
destroyed, the outer surface collapses and as a result, small pores 
are formed. The entrapped substance is drained, affecting the 
loading efficiency. Furthermore, it will concentrate towards the 
microparticle surface contributing to the initial burst release. 
Surface hollows could be attributed to the subsequent shrinkage of 
the microspheres after solidification [25]. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                         
 
 
 
 
 
 
          Figure 2. SEM micrographs of BET-loaded microspheres of formulations M1(a), M3(b), M4(c) and drug free microspheres (d)  
 at 5000x magnification. 
FTIR spectroscopy 
The infrared spectra of BET, chitosan, placebo and drug-loaded 
formulations are illustrated in Figure 3. BET depicted a broad band 
at 3414 cm-1, multiplet at 3100-2500 cm-1 overlapping absorption 
of pyridine ring, alkyl groups and ammonium ion (R-NH2+-) (Fig. 
3a). Absorption band at 773 cm-1 is ascribed to γ (out of plane) C-
H stretching of 2-substituted pyridines. The spectrum of placebo 
microsperes (Fig. 3b) shows peaks at 2928 cm-1, 1422 cm-1, 1154 
cm-1 which are attributed to alkyl groups (CH2). The peaks ranging 
between 2700-3000 cm-1 can be ascribed to the stretching of the 
NH2 group with strong overlapping hydroxyl peak between 3000-
3600 cm-1. Absorption at 1656  cm-1 and 1597cm-1 is due to -CO-
NHR group (amide I and amide II) present in the polymeric chain, 
as a result of the incomplete deacetylation of chitosan. Model 
systems (Fig. 3c) show broad bands at 3600-3100 cm-1 and 3000-
2700 cm-1 with increased absorption compared to chitosan. 
Intensity of all other peaks increases. Absorption peak appears at 
770 cm-1 due to BET. No new peaks were observed indicating the 
lack of new chemical bonds created  due to any interaction 
between BET and chitosan.
a 
 
b 
c d 
Pilicheva et al. International Journal of Drug Delivery 5 (4) 389-401 [2013] 
 
PAGE | 394 |
 
 
 
 
 
 
   
 
 
         
 
 
 
 
 
    
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
(b) 
Pilicheva et al. International Journal of Drug Delivery 5 (4) 389-401 [2013] 
 
PAGE | 395 |
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            Figure. 3 FTIR spectra of BET (a), placebo microspheres (b) and microsphere formulations (c) 
 
 
Thermal analysis 
In an effort to assess the physical state of the drug in the chitosan 
microspheres, we have analysed pure drug, placebo and BET-
loaded microsperes using TG-DTA. The thermograms are 
displayed on Figure 4. The drug (Fig. 4a) presented three 
endothermic peaks. The first peak is at 162.6ĈC and corresponds to 
the melting point. The decomposition process followed the melting 
of the drug observed as two endothermic effects.  As presented at 
Figure 4 (a), this sharp peak was dramatically reduced in the DTA 
thermograms of drug-loaded formulations (Fig. 4d). This result 
suggests that the crystallinity structure of BET was transformed 
into an amorphous state during the solvent evaporation process 
and the drug was molecularly dispersed inside the microspheres as 
supported by X-ray study. Nevertheless BET is hygroscopic in 
nature and is expected to retain significant amount of water in the 
microspheres, this was not observed and the endothermic peak 
assigning water loss from the formulations did not differ from the 
placebo particles. 
Two steps can be observed in the TG-curve of chitosan (Fig. 4b): 
the first one at about 84ĈC related to 6.3% weight loss was 
accompanied by endothermic effect and was attributed to the 
evaporation of water absorbed in the inner polymer. The second 
one, beginning at about 250ĈC and ending at over 400ĈC was 
connected with 42.2% weight loss and was indicated for 
vaporization and burning of volatile compounds produced from the 
thermal degradation of polymeric chain.  
In the DTA curve, a sharp exothermic peak was observed at 
320.6ĈC. According to some authors this event is related to the 
thermal decomposition of chitosan which occurs in the temperature 
range 270-337 ĈC due to deacetylation and depolymeryzation of 
chitosan. The decomposition temperature of placebo chitosan 
microspheres was 301.9ĈC, whereas that of BET-loaded 
formulations was lower (from 210 to 225ĈC). Considering the 
temperature at which thermal degradation starts as a criterion of 
the thermal stability of microparticulate formulations, it could be 
seen that the drug/ polymer ratio and BET entrapment influenced 
the thermal stability of the microspheres with respect to that of 
plain chitosan [26]. 
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Figure 4. TGA and DTA curves of pure betahistine (a), chitosan (b), placebo microspheres (c) and microsphere formulation M4 (d). 
X-ray diffraction analysis 
The X-ray diffractograms of BET, chitosan, placebo and drug-
loaded microspheres are shown in Figure 5. The X-ray diffraction 
pattern for BET displayed the presence of numerous distinct peaks; 
the diffractogram of pure chitosan powder showed two distinct 
peaks for the scattering angle 2θ, equal to 10.40 and 220 
approximately while the microparticulate formulations showed one, 
regardless of drug loading. According to this data BET was 
crystalline in nature while chitosan was amorphous. The molecular 
state of BET in the microparticles was changed from crystalline 
state to amorphous state. This shows that entrapped drug 
molecule is monomolecular dispersed in the polymer matrix.  
 
Figure 5. XRD patterns for pure BET, chitosan, blanc microspheres (placebo) and drug-loaded formulations (M1-M4). 
 
(d) 
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In vitro mucoadhesion 
In vitro mucoadhesion of the microspheres was the most important 
aspect of this study. Figure 6 summarizes the results of the tensile 
studies with BET-loaded formulations on sheep nasal mucosa. 
 
 
Figure 6. Mucoadhesive properties of microsphere formulations M1 ă M4 on sheep nasal mucosa. Mucoadhesion was evaluated by tensile 
studies and is expressed as the detachment force. Indicated values are means of five experiments. 
 
The results showed that all the batches had satisfactory 
mucoadhesive strength and could adequately adhere to nasal 
mucosa. Tensile studies performed with BET-loaded microsphere 
showed that drug/polymer ratio significantly influenced the 
mucoadhesive properties of the microspheres. Thus, the 
microspheres with equal BET/chitosan content (1:1, samples M1 
and M4) were more adhesive regardless the polymer concentration 
in the starting solution (1% w/v for M1; 2% w/v for M4). The lowest 
mucodhesion was observed with sample M3 (BET/chitosan 1:2) 
with a clear correlation between the amount of BET in the 
preparation and decrease in mucodhesion: the detachment force 
measured with BET/chitosan ratio 1:2 (sample M3), decreased 5-
fold (after 2 min contact time) and 2.5-fold (after 25 min contact) 
compared to the sample with the highest mucoadhesive strength - 
M1. This is most likely due to the higher polymer concentration in 
sample M3. High concentration of polymer imparts larger 
penetration with maximum adhesion. In few cases beyond optimum 
concentration, odd effects towards adhesive strength may occur. In 
highly concentrated systems, the adhesive strength drops 
significantly. In fact, in concentrated solutions, the coiled molecules 
become solvent poor and the chains available for interpenetration 
are fewer [27]. Another prerequisite for a good mucoadhesion is 
the high flexibility of polymer backbone structure since it is 
important for interpenetration and enlargement. The mobility of the 
individual polymer chain, however, is reduced if the polymer 
molecules become cross-linked.  Chitosan has a flexible, 
hydrophilic helical structure with reactive amine groups, which 
offers a multitude of possible inter- and intra-molecular interactions 
[28]. Lower amount of drug dispersed between polymer chains 
provides better opportunities for inter-chain conjunction and 
achieving a higher cross-linking degree. As the cross-linking 
density increases, the effective length of the chains which can 
penetrate into the mucus layer decreases. Although highly cross-
linked microspheres will absorb water, they are insoluble and will 
not form a liquid gel on the nasal epithelium but rather a more solid 
gel-like structure. The highly cross-linked microspheres are more 
rigid as compared to microspheres with low cross-linking degree 
and availability of the less number of sites for mucoadhesion, 
results in reduction in the mucoadhesive properties [29,30]. At the 
same time, there was no significant difference (p>0.05) in 
mucoadhesion between samples M2 and M4, indicating negligible 
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influence of drug and polymer concentrations in the starting 
solutions and drug/polymer ratio lower than 1:1.5. 
The initial contact time between microsphere formulations and the 
mucus layer was investigated as a factor affecting mucoadhesion. 
The initial contact time determines the extent of swelling and the 
interpenetration of polymer chains and thus can dramatically affect 
the performance of the system. Our results show that the 
mucoadhesive strength is enhanced as the initial contact time 
increases. No significant difference in the mucoadhesive strength 
of sample M1 was detected after various time itervals (2, 5, 10, 20, 
25 min) presenting excellent mucoadhesive behaviour irrespective 
of the initial contact time. This was probably due to the smaller 
particle size of this formulation and the uniform swelling manner ot 
the microspheres. Samples M2 and M4 show uneven particle size 
distribution and longer time will be needed to achieve equilibrium 
swelling. These formulations exhibit such mucoadhesive strength 
after 20 min initial contact time. 
In vitro release studies 
The dissolution profiles of BET-loaded formulations are shown in 
Figure 7. The release of drug from the polymer microparticles was 
controlled by the formation of a gel which slowed diffusion of the 
drug across the viscous boundary layer. It is reasonable to suggest 
that the prolonged release was the result of the gel formation. The 
percentage of drug release was found to be in the range of 56.08% 
to 64.98% at a period of 10 hours. Dissolution profiles show that 
BET was released from the microspheres in a biphasic way with 
initial rapid drug release (burst effect) from the surfaces of the 
particles followed by a step of slower release. The initial burst 
release was probably due to the accumulation of high drug 
amounts in the periphery of the microspheres during the intense 
solvent elimination and might be attributed as a desired effect to 
ensure the initial therapeutic plasma concentrations of drug. The 
drug in the core of particles is responsible for the prolonged drug 
release from the polymer matrix. The initial rapid drug leakage 
generally ended very early (within first 30-60 min); in the remaining 
time nearly linear behaviour was observed. Two phenomena can 
attribute to enhancing the diffusion of the remaining dispersed drug 
into the microspere matrix ă formation of pores within the matrix 
due to the initial drug dissolution and particle wetting and swelling 
which enhances the polymer permeability to the drug [31]. The 
release patterns of the samples were similar, with slight differences 
depending on the formulations drug loading and entrapment 
efficiency. Sample M1 had the lowest entrapment efficiency 
(69.37%) and released the smallest percentage of BET. At high 
loadings, major parts of the drug seem to be located close to the 
surface, easily accessible by the release medium. Sample M4 had 
the highest entrapmet efficiency (98.27%) and was expected to 
release maximum amount of BET. However, our suggestions were 
not confirmed and sample M4 released smaller amount of BET 
than M3. This was probably due to the larger particle size of this 
formulation. Usually, the release of drugs from larger microparticles 
is slower than that from the smaller ones due to a smaller surface 
area subject to dissolution [32]. At the end of 10h release of BET 
was incompelte in all the batches indicating that the chitosan gel 
layers were too swolen and viscous and hindered the outward 
transport of core located drug molecules.  
To find out the mechanism of drug release, the obtained drug 
release data were fitted in Korsmeyer-Peppas model. This model is 
generally used to analyse the release of pharmaceutical polymeric 
dosage forms, when the release mechanism is not well known or 
when more than one type of release phenomena could be involved 
[33]. For these cases, a general equation can be used: 
Mt  / M¥ = Ktn 
where Mt  / M¥  is the fraction of drug released at time t, K is kinetic 
constant incorporating structural and geometric characteristics of 
the delivery system, n is the diffusional exponent and is indicator of 
the mechanism of transport of drug through the polymer. In the 
case of spherical matrices, n ª 0.45 corresponds to a diffusion 
control (Fickian release), 0.45 < n ª 0.89 to non-Fickian or 
anomalous, n = 0.89 to Case II (relaxational) transport, and n > 
0.89  super case II transport. For determination of exponent n the 
portion of the release curve was used up to Mt / M¥ < 0.6 [34]. The 
n values as shown in Table 2 were in the range of 0.1810 to 0.2078 
indicating that all the prepared formulations followed the Fickian-
diffusion controlled mechanism of drug release. 
 
Table 2. Kinetic (Korsmeyer-Peppas model) parameters of BET 
release from chitosan microspheres 
Formulation 
code 
K R2 n
M1 0.3921 0.8348 0.1810
M2 0.3815 0.8335 0.1853
M3 0.3441 0.8680 0.2008
M4 0.3503 0.8889 0.1875
K - kinetic constant; R2 - coefficient of determination; n - diffusional 
exponent. 
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Figure 7. Dissolution profiles of BET from microsphere formulations prepared at different drug/polymer ratio. Each data point represents the 
mean value μSD of three determinations. 
Conclusions 
In the present study BET-loaded chitosan microspheres were 
prepared using emulsion solvent evaporation technique. The 
microspheres were produced with sufficient production yield and 
high entrapment efficiency confirming the simplicity and 
reproducibility of the method described above. The microspheres 
were at a suitable size and had excellent surface morphology. No 
chemical reactions were observed between BET and chitosan 
indicating excellent drug/polymer compatibility. The mucoadhesive 
properties of the microspheres were strongly influenced by 
drug/polymer ratio and chitosan concentration had significant effect 
on BET release rate. The dissolution profiles were similar and 
slightly increasing when higher concentration of chitosan was used. 
These results clearly indicate that the chitosan microspheres have 
the potential to deliver BET following nasal administration and 
could be used as a sustained-release drug delivery system. 
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